Navigation Links
'Alliance for Medical Devices, Instrumentation and Diagnostics' formed between Fraunhofer Center for Manufacturing Innovation and Boston University
Date:9/10/2007

PLYMOUTH, Mich., Sept. 10 /PRNewswire/ -- The primary objective of the Alliance is to improve patient care by accelerating the delivery of biomedical advances to the marketplace.

To celebrate the Alliance, a symposium was held at Boston University on Friday, September 7th with noted speakers from industry, government, entrepreneurs, venture capitalists and the Presidents of both Boston University and Fraunhofer Gesellschaft.

The alliance will take advantage of the two institutions' respective strengths. Advanced biomedical research is being conducted throughout BU's College of Engineering, College of Arts and Sciences, and Medical School, resulting in many potential medical innovations. Fraunhofer hopes to take these innovations and convert them into working medical devices and instruments that can be licensed to existing companies or created by new, spin-off ventures. The Alliance will leverage the most promising research innovations in labs through Boston University, particularly in its College of Engineering, with the goal of making a significant impact on the way clinical medicine is practiced.

Fraunhofer Gesellschaft is very active in biomedical research. Current activities include plant-based vaccine development, medical imaging, array- based diagnostics, surgical micro-tools development, and other novel devices and instrumentation.

The Fraunhofer Center for Manufacturing Innovation was established at Boston University in 1995. Working with BU faculty, students and international interns, the engineers at the Center scale-up basic research into advanced technologies that meet the needs of client companies both locally and globally. The focus of the Center is on the development of next-generation instruments and high precision automation systems for the biotech/biomedical, photonics, and semiconductor industries.

Boston University Professor Andre Sharon, who is also Executive Director of the Fraunhofer Center for Manufacturing Innovation stated, "The alliance will leverage the most promising research innovations in labs throughout Boston University, particularly in its College of Engineering."

BU College of Engineering Dean Kenneth R. Lutchen stated "This initiative will further accelerate our most promising research in this area so improved medical care can be delivered to patients as soon as possible."

To learn more about Fraunhofer USA, Inc., please visit http://www.fraunhofer.org.

Fraunhofer USA, Inc. is a non-profit research and development corporation, with headquarters in Michigan. It operates through technology centers that are partnered with major research universities in the United States and also with parent research institutes in Germany.

Contact: Frances Roland-Lee

+1-734-354-4333

froland@fraunhofer.org


'/>"/>
SOURCE Fraunhofer USA
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Biomedical Alliance about more than stem cells
2. Doyle seeks $2.5M for biomedical alliance
3. Alliance looks to create the right chemistry in SE Wisconsin
4. Biomedical alliance marks first full year
5. New alliance to provide Wi-Fi network for City of Madison
6. Budget axe could cut SE Wisconsin tech alliance funding
7. Biotech Alliance pushes ahead in SE Wisconsin with likely state funding
8. Milwaukee research alliance sees need for incubator
9. University alliance gets $2.5 million to encourage minorities in science and technology
10. Suite Scheduler Announces Alliance with Ice Technologies
11. Alliance Brings E-Business Technologies to Wisconsin Manufacturers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on ... of Mental Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ... is expected to deliver therapeutic levels of olanzapine for a period of 3 months., ...
(Date:2/24/2017)... 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, ... clinical-stage oncology and dermatology biopharmaceutical company, today is ... in its previously announced rights offering of up ... common stock and Series C Convertible Preferred Stock ... As previously announced, the rights ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... -- China Cord Blood Corporation (NYSE: CO ... cord blood collection, laboratory testing, hematopoietic stem cell processing ... financial results for the third quarter and first nine ... Third Quarter of Fiscal 2017 Highlights ... 2017 increased by 18.6% to RMB200.9 million ($28.9 million). ...
Breaking Biology Technology:
(Date:2/8/2017)... Inc. (NASDAQ: AWRE ), a leading supplier of ... quarter and year ended December 31, 2016. ... compared to $6.9 million in the same quarter last year. ... million compared to $2.6 million in the fourth quarter of ... $0.5 million, or $0.02 per diluted share, which compares to ...
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
(Date:2/3/2017)... Biomedical Research Institute announced that its Board of Trustees has ... Institute,s new President and CEO. Dr. Schlesinger will take the ... currently the Chair of the Department of Microbial Infection and ... at Ohio State University. "We are delighted to ... Texas Biomed," said Dr. James O. Rubin , Board ...
Breaking Biology News(10 mins):